Overview

• Vivos Q3 2025 revenue rises 76% yr/yr, driven by SCN acquisition

• Company's gross margin declines to 58% from 60% due to pricing discounts

• Operating expenses increase 74% due to SCN acquisition-related costs

Outlook

• Vivos expects near-term expenses to rise due to investments in SCN operations

• Company plans to expand sleep center model beyond Las Vegas

• Vivos anticipates seeing patients at new Michigan location by December

Result Drivers

• SCN ACQUISITION IMPACT - Vivos attributes 78% sequential revenue growth to the acquisition of The Sleep Center of Nevada

• STRATEGIC PIVOT - Co's shift from dental distribution to direct medical affiliations drives revenue increase

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Vivos Therapeutics Inc is $6.50, about 62% above its November 18 closing price of $2.47

Press Release: ID:nGNX32j7qg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)